The World's Greatest Investing Community
Results 1 - 10 of 215 : 1 2 3 4 5 6 7 8 9 Next
This stock just hit a 52-week milestone. Where will it head from here?
Tysabri's Looking Good at a Crossroads
Sales up despite potential to lose half the patients.
6 Buy-Rated Stocks With Encouraging Receivable Trends
What Oppenheimer's bullish on.
Big Pharma Cozies Up to Biotech
If you can't beat 'em, join 'em.
The Disadvantage of a Successful Pipeline
Biogen ramps up R&D spending.
Biogen Idec Outruns Estimates Again
Just the facts, Fool.
Which Big Biotech Is the Best Bet?
That might depend on which kind of investor you are.
50% of This Market Would Be Just Fine
Biogen and Elan stratify Tysabri's PML risk.
Is Biogen's Stock Reasonable by the Numbers?
Let's take a look.
BATS data provided in real-time. NYSE, NASDAQ and AMEX data delayed 15 minutes.
Real-Time prices provided by BATS. Market data provided by Interactive Data.
Company fundamental data provided by Morningstar. Earnings Estimates and Analyst Ratings provided by Zacks.
SEC Filings and Insider Transactions provided by Edgar Online.
Powered and implemented by Interactive Data Managed Solutions. Terms & Conditions
RSS Headlines
Fool UK